positive living with MS
Please select your professional status below if you are a medical professional or click here to return to the msactivesource.co.uk website if you are not.
Clicking on the relevant title certifies that you are a healthcare professional accessing in your capacity as a healthcare professional.
MS Nurse...click here
Nurse...click here
Doctor...click here
MS Specialist...click here
You are leaving www.msactivesource.co.uk, a web site of Biogen Idec UK & Ireland. Links to all outside web sites are provided as a resource to our visitors. Biogen Idec accepts no responsibility for the content of other web sites.
Tysabri (natalizumab) belongs to a novel class of drug known as selective adhesion molecule (SAM) inhibitor; it is also a disease modifying treatment (DMT); however it works in a different way to older DMTs.
Natalizumab, the active substance in Tysabri, is a monoclonal antibody that has been designed to recognise and bind to a specific structure (an antigen) that is that is found on certain cells in the body. This structure is called an integrin; the integrin is found on the surface of the white cells in the blood which are involved in the inflammation process of MS. By attaching to the integrin, natalizumab stops the white blood cells from moving the blood stream into the brain. This reduces inflammation, and the nerve damage caused by MS.
Tysabri is used to treat patients who have highly active relapsing remitting MS.
Tysabri is marketed by Biogen Idec Ltd and Elan Pharma International Ltd in the UK and Ireland.
Tysabri was recommended for use on the NHS in England and Wales by NICE in July 2007. (refT5)
Use of this product will be determind by your neurologist according to guidance layed out in the risk-sharing scheme. More information can be found by going to www.mstrust.org.uk
More detailed prescribing information on Tysabri can be found by going to www.medicines.org.uk. Typing Tysabri in the search box and pressing Go will bring you to a patient information leaflet on Tysabri.
How MS affects you will be very different to how it affects someone else.
Supported by
This website is intended for use in Great Britain and Northern Ireland.
Please click here for msactivesource.ie
Page last updated: 29 Jun 2009
|
| This site complies to the HONcode standard for trustworthy health information: verify here. |